ストックスクリーナーアプリを入手
1.37
1.44%
-0.02
アフターアワーズ：
1.43
0.06
+4.38%
前日終値:
$1.39
開ける：
$1.45
24時間の取引高:
26,272
Relative Volume:
0.18
時価総額：
$39.51M
収益：
$40.58M
当期純損益:
$-80.65M
株価収益率:
-0.4113
EPS:
-3.331
ネットキャッシュフロー:
$-8.11M
1週間 パフォーマンス:
+4.58%
1か月 パフォーマンス:
+13.22%
6か月 パフォーマンス:
-36.28%
1年 パフォーマンス:
-7.43%
1日の値動き範囲:
$1.37
$1.45
1週間の範囲:
$1.29
$1.45
52週間の値動き範囲:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.37 | 40.08M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey - Defense World
Exclusive: NexGel to acquire regenerative biomaterial portfolio from Celularity, expects to triple revenue - MSN
Barach Family Trust Secures Board Observer Role at Celularity with 9.56% Stake - TradingView
Barach Family Trust backs Celularity (CELU) with $10M notes and 9.56% stake - Stock Titan
Celularity Inc. (CELU) stock price, news, quote and history - Yahoo Finance UK
Celularity Delays Annual 10-K Filing Amid Strains - TipRanks
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - marketscreener.com
NEXGEL delays earnings call a week to add detail on Celularity deal - Stock Titan
Market Review: Can Celularity Inc outperform in the next rallyTrade Risk Report & Expert Approved Momentum Ideas - baoquankhu1.vn
NEXGEL to pay $15 million for Celularity regenerative biomaterial portfolio - msn.com
Aug Analyst Calls: Is Celularity Inc Equity Warrant forming higher highs and higher lows2026 Major Catalysts & Fast Moving Trade Plans - baoquankhu1.vn
Death Cross: Why is Celularity Inc stock going upWeekly Market Report & Entry Point Strategy Guides - baoquankhu1.vn
Portfolio Update: Is Celularity Inc Equity Warrant a top pick in the sector2026 Fundamental Recap & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Update Recap: Will Celularity Inc Equity Warrant benefit from AI trendsQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Fund Flows: Can Celularity Inc stock outperform in a bear marketEarnings Recap Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Gains Report: Is Celularity Inc a stock for growth or value investors - baoquankhu1.vn
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Growth Review: Can Celularity Inc sustain earnings growthMarket Movement Recap & Low Risk High Reward Ideas - baoquankhu1.vn
If You Invested $1,000 in Celularity Inc (CELU) - Stock Titan
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
1.75%
大文字化:
|
ボリューム (24 時間):